English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Fifty patients with acute deep venous thrombosis in the leg were randomly allocated to either two daily subcutaneous injections (S.C.) or continuous intravenous infusion (I.V.) of heparin for at least five days. Most patients were given coumarols from the first day of heparin treatment. The amount of heparin required to maintain a prolongation of the APT-time 1 1/2 to 3 1/2 times was the same in both groups and daily heparin dosages varied between 25.000 and 50.000 units. Antithrombin III activity (AT III) was measured daily during heparin treatment and in some patients also AT III estimations were performed 1 to 12 months after heparin treatment i.e. during and after coumarol treatment.  Results: The mean concentration of AT III decreased progressively in both groups during heparin treatment from about 95% to 70%. The decrease in AT III was the same in patients treated with heparin S.C. as in patients treated with heparin I.V.

Antithrombin III Activity During Intravenous And Subcutaneous Treatment With Heparin In Patients With Venous Thrombosis